肺炎奴卡菌合并天美奴卡菌肺部感染1例报道并文献复习

doi:10.6040/j.issn.1671-7554.0.2021.0092

摘要/Abstract

摘要： 目的探讨肺炎奴卡菌和天美奴卡菌肺部感染的临床特征及治疗选择。方法总结和分析1例肺部肺炎奴卡菌合并天美奴卡菌感染患者的临床特征及治疗转归,并检索有关资料进行文献复习。结果该患者为免疫功能低下及结构性肺病患者,临床表现为发热、咳脓痰、呼吸困难。CT表现为双肺多发大小不等结节影、团块影及实变影,可见空洞形成,洞壁上有赘生物样突起;伴液气胸。经BALF mNGS及胸水培养加质谱分析确诊为肺炎奴卡菌和天美奴卡菌感染,两菌对利奈唑胺、复方新诺明、亚胺培南、头孢曲松敏感,对喹诺酮类耐药。结论肺炎奴卡菌和天美奴卡菌是肺部感染的重要病原菌,利奈唑胺联合亚胺培南及复方新诺明是其有效的治疗措施。

关键词: 肺部感染, 肺炎奴卡菌, 天美奴卡菌, 宏基因组二代测序, 抗菌药物

Abstract: Objective To describe the clinical characteristics and treatment options of Nocardia pneumoniae and Nocardia amamiensis pulmonary infection. Methods The clinical characteristics and treatment option of a patient with Nocardia pneumoniae and Nocardia amamiensis pulmonary infection were collected and analyzed. A series of relevant literature was reviewed. Results The patient was an immunocompromised host and had structural lung disease. The clinical manifestations were fever, expectoration and dyspnea. Chest CT showed multiple nodules, masses and consolidation in both lungs, with cavity formation, protrusions on the wall of cavity and liquid pneumothorax. The pathogens were identified as Nocardia pneumoniae and Nocardia amamiensis by BALF mNGS and pleural fluid bacteria culture with mass spectrometry analysis. Both of the bacteria were susceptible to linezolid, trimethoprim-sulfamethoxazole, imipenem and ceftriaxone, and resistant to quinolones. Conclusion Nocardia pneumoniae and Nocardia amamiensis are important pathogens of pulmonary infection. Combined linezolid and imipenem with trimethoprim-sulfamethoxazole is an effective anti-infection therapy.

Key words: Pulmonary infection, Nocardia pneumoniae, Nocardia amamiensis, Metagenomic next-generation sequencing, Antibiotics

中图分类号:

R519

安袁笑雪,杜以明,田甜,张一,薛玉文. 肺炎奴卡菌合并天美奴卡菌肺部感染1例报道并文献复习[J]. 山东大学学报 (医学版), 2022, 60(3): 59-63.

AN Yuanxiaoxue, DU Yiming, TIAN Tian, ZHANG Yi, XUE Yuwen. Pulmonary infection caused by Nocardia pneumoniae and Nocardia amamiensis: a case report and literature review[J]. Journal of Shandong University (Health Sciences), 2022, 60(3): 59-63.

参考文献

[1] Weng SS, Zhang HY, Ai JW, et al. Rapid detection of Nocardia by next-generation sequencing[J]. Front Cell Infect Microbiol, 2020, 10: 13. doi:10.3389/fcimb.2020.00013.
[2] Kageyama A, Yazawa K, Mukai A, et al. Nocardia araoensis sp. nov. and Nocardia pneumoniae sp. nov., isolated from patients in Japan[J]. Int J Syst Evol Microbiol, 2004, 54(Pt 6): 2025-2029.
[3] Yamamura H, Tamura T, Sakiyama Y, et al. Nocardia amamiensis sp. nov., isolated from a sugar-cane field in Japan[J]. Int J Syst Evol Microbiol, 2007, 57(Pt 7): 1599-1602.
[4] Fatahi-Bafghi M. Nocardiosis from 1888 to 2017[J]. Microb Pathog, 2018, 114: 369-384. doi: 10.1016/j.micpath.2017.11.012.
[5] Conville PS, Brown-Elliott BA, Smith T, et al. The complexities of Nocardia taxonomy and identification[J]. J Clin Microbiol, 2017, 56(1): e01419-01417.
[6] Beaman BL, Burnside J, Edwards B, et al. Nocardial infections in the United States, 1972-1974[J]. J Infect Dis, 1976, 134(3): 286-289.
[7] Lynch JP, 3rd, Reid G, Clark NM. Nocardia spp.: a rare cause of pneumonia globally[J]. Semin Respir Crit Care Med, 2020, 41(4): 538-554.
[8] Lafont E, Conan PL, Rodriguez-Nava V, et al. Invasive Nocardiosis: disease presentation, diagnosis and treatment-old questions, new answers?[J]. Infect Drug Resist, 2020, 13: 4601-4613. doi: 10.2147/IDR.S249761.
[9] Yu JE, Azar AE, Chong HJ, et al. Considerations in the diagnosis of chronic granulomatous disease[J]. J Pediatric Infect Dis Soc, 2018, 7(suppl_1): S6-S11.
[10] Ercibengoa M, Càmara J, Tubau F, et al. A multicentre analysis of Nocardia pneumonia in Spain: 2010-2016[J]. Int J Infect Dis, 2020, 90: 161-166. doi: 10.1016/j.ijid.2019.10.032.
[11] Abe S, Tanabe Y, Ota T, et al. Case report: pulmonary nocardiosis caused by Nocardia exalbida in an immunocompetent patient[J]. BMC Infect Dis, 2021, 21(1): 776.
[12] Wang T, Jia Y, Chu B, et al. Nocardiosis in kidney disease patients under immunosuppressive therapy: case report and literature review[J]. Int J Med Sci, 2019, 16(6): 838-844.
[13] Kato K, Noguchi S, Naito K, et al. Pulmonary Nocardiosis caused by Nocardia exalbida in a patient with lung cancer and radiation pneumonitis: a case report and literature review[J]. Intern Med, 2019, 58(11): 1605-1611.
[14] 余仙娟,何飞,汝触会. 播散性天美奴卡菌病一例临床分析并文献复习[J]. 浙江中西医结合杂志, 2020, 30(5): 413-416.
[15] 中华医学会检验医学分会临床微生物学组,中华医学会微生物学与免疫学分会临床微生物学组,中国医疗保健国际交流促进会临床微生物与感染分会.宏基因组高通量测序技术应用于感染性疾病病原检测中国专家共识[J].中华检验医学杂志, 2021, 44(2): 107-120. Clinical Microbiology Group of Chinese Society of Laboratory Medicine, Clinical Microbiology Group of Chinese Society of Microbiology and Immunology, Society of Clinical Microbiology and Infection of China International Exchange and Promotion Association for Medical and Healthcare. Chinese expert consensus on metagenomics next-generation sequencing application on pathogen detection of infectious diseases[J]. Chinese Journal of Laboratory Medicine, 2021, 44(2): 107-120.
[16] Gu W, Miller S, Chiu CY. Clinical metagenomic next-generation sequencing for pathogen detection[J]. Annu Rev Pathol, 2019, 14: 319-338. doi: 10.1146/annurev-pathmechdis-012418-012751.
[17] Betrán A, Villuendas MC, Rezusta A, et al. Clinical significance, antimicrobial susceptibility and molecular identification of Nocardia species isolated from children with cystic fibrosis[J]. Braz J Microbiol, 2016, 47(3): 531-535.
[18] Brown-Elliott BA, Brown JM, Conville PS, et al. Clinical and laboratory features of the Nocardia spp. based on current molecular taxonomy[J]. Clin Microbiol Rev, 2006, 19(2): 259-282.
[19] Hansen G, Swanzy S, Gupta R, et al. In vitro activity of fluoroquinolones against clinical isolates of Nocardia identified by partial 16S rRNA sequencing[J]. Eur J Clin Microbiol Infect Dis, 2008, 27(2): 115-120.
[20] Yi M, Wang L, Xu W, et al. Species distribution and antibiotic susceptibility of Nocardia isolates from Yantai, China[J]. Infect Drug Resist, 2019, 12: 3653-3661. doi: 10.2147/IDR.S232098.
[21] Huang L, Chen X, Xu H, et al. Clinical features, identification, antimicrobial resistance patterns of Nocardia species in China: 2009-2017[J]. Diagn Microbiol Infect Dis, 2019, 94(2): 165-172.
[22] Valdezate S, Garrido N, Carrasco G, et al. Epidemiology and susceptibility to antimicrobial agents of the main Nocardia species in Spain[J]. J Antimicrob Chemother, 2017, 72(3): 754-761.
[23] Lebeaux D, Bergeron E, Berthet J, et al. Antibiotic susceptibility testing and species identification of Nocardia isolates: a retrospective analysis of data from a French expert laboratory, 2010-2015[J]. Clin Microbiol Infect, 2019, 25(4): 489-495.
[24] Uhde KB, Pathak S, McCullum I Jr, et al. Antimicrobial-resistant nocardia isolates, United States, 1995-2004[J]. Clin Infect Dis, 2010, 51(12): 1445-1448.
[25] Davidson N, Grigg MJ, McGuinness SL, et al. Safety and outcomes of linezolid use for Nocardiosis[J]. Open Forum Infect Di, 2020, 7(4): ofaa090.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed